Two doses of Pfizer “are 99.96% effective,” the investigation in Israel suggests

by

Two doses of Pfizer “are 99.96% effective”: two weeks apart prevent almost ALL cases of Covid-19, according to research in Israel

  • Israeli research has shown that only 0.04% of those vaccinated with the two doses of the Pfizer / BioNTech vaccine developed coronavirus
  • Of the 700,000 vaccinated people, only 300 later contracted Covid-19, and only 16 required hospital treatment, according to preliminary data.
  • The vaccine also protects against the most infectious variant in the UK, according to research

By Katie Pickles, Daily Mail health correspondent

Posted: | Updated:

Research suggests that almost all cases of Covid are avoided with two doses of the Pfizer vaccine.

Data collected in Israel, which is the world leader in vaccine deployment, found that only 0.04% of those vaccinated with the two doses developed coronavirus.

Of the 700,000 vaccinated people, only 300 contracted the virus later, and only 16 required hospital treatment, according to preliminary data released by Israeli health officials.

The vaccine also protects against the infectious variant of Covid-19 in the UK, according to research.

Professor Eyal Leshem, an Israeli infectious disease specialist, said the reports were “very good news”. He added: “The initial findings are quite incredible.

Research suggests that almost all cases of Covid are avoided with two doses of the Pfizer vaccine. Data collected in Israel, which is the world leader in vaccine deployment, found that only 0.04% of those vaccinated with the two doses developed coronavirus. In the photo: a man receives a dose of the Pfizer / BioNTech vaccine in Tel Aviv, Israel on Tuesday

Research suggests that almost all cases of Covid are avoided with two doses of the Pfizer vaccine. Data collected in Israel, which is the world leader in vaccine deployment, found that only 0.04% of those vaccinated with the two doses developed coronavirus. In the picture: A man receives a dose of the Pfizer / BioNTech vaccine in Tel Aviv, Israel on Tuesday

“After one dose, the cases dropped substantially and after two, there was only 0.4 percent.

“Time will tell, we still need to accumulate data, but these are very encouraging preliminary reports.”

More than 30% of the Israeli population has received a vaccine, with several studies on its effectiveness in progress.

Professor Leshem added: “On the one hand, we see very high community transmission rates with 1,000 cases each day, the highest rates we have experienced since the outbreak began.

“But when we look specifically at these hundreds of thousands of vaccinated Israelis, they don’t get infected.

In the photo: Health workers at the Maccabi Health vaccination center administer doses of the Pfizer / BioNTech vaccine on Tuesday in the parking lot of the Givatayim shopping center in Tel Aviv, Israel, on Tuesday

In the photo: Health workers at Maccabi Health Vaccination Center administer doses of Pfizer / BioNTech vaccine on Tuesday in the parking lot of Givatayim Mall in Tel Aviv, Israel

And even in these few cases that become infected, they experience a mild illness: only a handful have to go to the hospital, only a handful have experienced a serious illness, and they have to be hospitalized.

“It’s what we call real life, ecological evidence of vaccine efficacy: high vaccine efficacy.”

Most of the vaccinated were over 60 years old, which made the results even more remarkable, he added.

Initial studies have also found a significant reduction in cases among those who have had a dose of the vaccine.

Israel provides Pfizer with weekly updates of data on its vaccination campaign under a partnership agreement.

  • A leaked document has revealed that Iran will buy the Oxford-AstraZeneca vaccine through the back door despite banning “unreliable” British vaccines. Iran banned vaccines from the United Kingdom and the United States on January 8, but in a radical change, the nation would buy 36 million doses of the Oxford vaccine through India.

.Source